

3 September 2009

Proposal for Dr Reddy's Risperidone

PHARMAC is seeking feedback on a proposal to fund a new brand of risperidone tablets (Dr Reddy's Risperidone) through a provisional agreement with Dr Reddy's New Zealand Ltd.

Key aspects of the proposal

Under this proposal, Dr Reddy's Risperidone would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 December 2009 at the following prices and subsidies (ex-manufacturer, excluding GST):

Pharmaceutical	Brand	Form and Strength	Pack Size	Proposed price and subsidy
Risperidone	Dr Reddy's Risperidone	Tab 0.5 mg	20	\$1.17
Risperidone	Dr Reddy's Risperidone	Tab 1 mg	60	\$6.00
Risperidone	Dr Reddy's Risperidone	Tab 2 mg	60	\$11.00
Risperidone	Dr Reddy's Risperidone	Tab 3 mg	60	\$15.00
Risperidone	Dr Reddy's Risperidone	Tab 4 mg	60	\$20.00

No subsidy or delisting protection would apply to Dr Reddy's Risperidone and the listing of the 0.5 mg strength would be subject to Medsafe approval.

Effects of the proposal on other subsidised brands of risperidone

This proposal to list Dr Reddy's Risperidone would not affect the subsidy for any other brand of risperidone that is listed in the Pharmaceutical Schedule at 1 December 2009 – they would remain fully funded for at least the duration of the relevant subsidy protection applying to each brand. Subsidy protection end dates for the various brands of risperidone for which funding has been approved are as follows:

Risperdal tablets and oral liquid (Janssen-Cilag)	1 July 2012
Ridal tablets (Douglas Pharmaceuticals)	1 February 2010
Risperon oral liquid (Mylan NZ)	1 July 2012
Apo-Risperidone tablets and oral liquid (Apotex NZ)	1 July 2012

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **4 pm on Friday 18 September 2009** to:

Geraldine MacGibbon	Email: geraldine.macgibbon@pharmac.govt.nz
Therapeutic Group Manager	Fax: (04) 460 4995
PHARMAC	Post: PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.